<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200502047277N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-29</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Steroids in posterior spinal fusion</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effects of local intraoperative epidural use of triamcinolone-soaked Gelfoam with normal saline -soaked Gelfoam on postoperative outcomes in patients undergoing posterolateral lumbar spinal fusion surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-10-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58944</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization (1:1) with a block size of 4 will be performed using the SPSS 24, and sealed opaque envelopes will be used for allocation concealment. In SPSS, after dividing the study population into blocks, random numbers between 0 and 1 will be generated for each patient using RV.UNIFORM(0,1) and after determining the rank within each block, the two lower ranks will be assigned to treatment group 1, and the two upper ranks will be assigned to treatment group 2. Except for the surgeon performing the study intervention, patients, principal investigator, outcome assessors, and data analyzers will remain blind to the randomization and allocation, Blinding description: Patients, the principal investigator, outcome assessors, and data analyzers will be blind to the study intervention. For allocation concealment, sealed opaque envelopes will be used (treatment 1 or 2). Due mainly to the nature of the study intervention, the surgeon will not be blind to the allocation process and intervention received by the patients and will perform the study intervention or placebo based on the study group (treatment 1 or 2). The surgeon will remain out of the process of data collection, outcome assessment, or analysis. Postoperatively, all patients, outcome assessors and analyzers, and the principal investigator will only know the study group (treatment 1 or 2) and will remain blind to the intervention performed in each group throughout the study.</study_design>
      <phase>3</phase>
      <hc_freetext>Fusion of spine, lumbar region.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: A Gelfoam soaked in 1 ml of triamcinolone acetonide (40 mg/ml, TriamHEXAL; HEXAL AG, Holzkirchen, Germany) for five minutes, will be placed placed over the nerve roots. After the placement of Gelfoam, the surgical closure will be performed. Intervention 2: Control group: Similar to the treatment group, a Gelfoam soaked in 1 ml of normal saline for five minutes, will be placed over the nerve roots. After the placement of Gelfoam, the surgical closure will be performed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Roozbeh Tavanaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Functional Neurosurgery Research Center (FNRC), SBMU Shohada-E-Tajrish Educational Hospital, Tajrish Sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1989934148</zip>
        <telephone>+98 21 2270 1022</telephone>
        <email>rtavanaei@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Saeed Oraee yazdani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Tajrish</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1989934148</zip>
        <telephone>+98 21 25719</telephone>
        <email>saeed_o_yazdani@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age greater than 18 years
Degenerative indications for elective posterior instrumented lumbar spinal fusion surgery
Written informed consent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Non-degenerative pathologies (e.g., tumor, trauma, deformity, or infection)
Hypersensitivity reaction to the study drug
American Society of Anesthesiologists (ASA) physical status&gt; 2
Concurrent psychiatric disorder</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M43.26</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fusion of spine, lumbar region</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: A Gelfoam soaked in 1 ml of triamcinolone acetonide (40 mg/ml, TriamHEXAL; HEXAL AG, Holzkirchen, Germany) for five minutes, will be placed placed over the nerve roots. After the placement of Gelfoam, the surgical closure will be performed.</i_keyword>
      <i_keyword>Control group: Similar to the treatment group, a Gelfoam soaked in 1 ml of normal saline for five minutes, will be placed over the nerve roots. After the placement of Gelfoam, the surgical closure will be performed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>10-point visual analog scale (VAS) for postoperative pain. Timepoint: baseline, 2, 4, 6, 12, 24, and 48 h with 1, 4, and 12 weeks  postoperatively. Method of measurement: Visual analog scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Cumulative postoperative 24 h morphine consumption. Timepoint: 24 h postoperatively. Method of measurement: Patient-controlled analgesia device.</sec_outcome>
      <sec_outcome>Oswestry disability index (ODI). Timepoint: 1 and 4 weeks postoperatively. Method of measurement: Questionnaire.</sec_outcome>
      <sec_outcome>Length of stay. Timepoint: Until discharge. Method of measurement: follow-up.</sec_outcome>
      <sec_outcome>Postoperative nausea and vomiting. Timepoint: Every 4 h for 24 h postoperatively. Method of measurement: follow-up and observation.</sec_outcome>
      <sec_outcome>Postoperative complications. Timepoint: Once a week for 12 weeks after the surgery. Method of measurement: follow-up and observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-11-22</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti University of Medical Sciences ,Shahid Arabi St., Yemen St., Shahid Chamran Highway, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
